(8CI)-嘧啶并[5,4-d]嘧啶-2-醇 | 28285-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (8CI)-嘧啶并[5,4-d]嘧啶-2-醇
• 英文名称: Pyrimido[5,4-d]pyrimidin-2(1H)-one
• 英文别名: 1H-pyrimido[5,4-d]pyrimidin-2-one
• CAS: 28285-66-7
• 化学式: C₆H₄N₄O
• 分子量: 148.12
• InChiKey: RLJCWYYOGHGGBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS<br/>[FR] UTILISATION D'INHIBITEURS DE KINASES POUR FAVORISER LA NEOCHONDROGENESE
  申请人：WARNER LAMBERT CO

  公开号：WO2006038112A1

  公开（公告）日：2006-04-13

  This invention provides methods for utilizing compounds that inhibit cyclin­dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula (I): and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1,R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.

  本发明提供了一种利用抑制周期素依赖性激酶和酪氨酸激酶的化合物来促进新软骨生成以及增强、保护和修复软骨的方法。在某些实施方式中，本发明涉及使用公式(I)的化合物以及药用可接受的盐来促进新软骨生成，其中R1、R2、R3、R4、R5、R6、A、B、D和E具有说明书中为其定义的任何值。
• Kinase inhibitors
  申请人：——

  公开号：US20040019210A1

  公开（公告）日：2004-01-29

  This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines, and pyridopyrazines of the general formula: 1 that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis, as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliferative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.

  本发明提供了抑制周期蛋白依赖性激酶和酪氨酸激酶酶的通用公式： 1 的苯基取代嘧啶嘧啶、二氢嘧啶嘧啶、嘧啶嘧啶、萘啶和嘧啶吡唑，以及用于合成它们的中间化合物、药物组合物和用于治疗、抑制或预防与细胞增殖紊乱相关的疾病，包括血管生成、动脉粥样硬化、再狭窄和癌症。
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
  申请人：WARNER LAMBERT CO

  公开号：WO2004011465A1

  公开（公告）日：2004-02-05

  This invention provides phenyl-substituted pyrimidopyrimidines, dihydropyrimido-pyrimidines, pyridopyrimidines, naphthyridines,and pyridopyrazines of the general formula (I) that inhibit cyclin-dependent kinase and tyrosine kinase enzymes, methods and intermediate compounds for their synthesis,as well as pharmaceutical compositions and methods for their use in treating, inhibiting or preventing maladies associated with cell proliverative disorders, including angiogenesis, atherosclerosis, restenosis, and cancer.

  该发明提供了通式（I）中的苯基取代的嘧啶嘧啶、二氢嘧啶嘧啶、吡啶嘧啶、萘嘧啶和吡啶吡嗪，这些化合物可以抑制细胞周期依赖性激酶和酪氨酸激酶酶，同时提供了其合成的方法和中间体化合物，以及用于治疗、抑制或预防与细胞增殖紊乱相关的疾病，包括血管生成、动脉粥样硬化、再狭窄和癌症的制剂和方法。
• [EN] PYRIMIDOPYRIMIDINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] COMPOSÉ DE PYRIMIDOPYRIMIDINONE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT<br/>[KO] 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물
  申请人：AXCESO BIOPHARMA CO LTD

  公开号：WO2022060094A1

  公开（公告）日：2022-03-24

  본 발명은 PD-L1 발현을 억제하는 효과를 가지는 피리미도 피리미디논 화합물 및 그를 유효성분으로 포함하는 약제학적 조성물에 관한 것이다. 본 발명의 피리미도 피리미디논 화합물은 암의 치료 또는 예방에 효과적으로 사용될 수 있다.

  本发明涉及一种含有皮里米多皮里米酮化合物及其有效成分的药学组合物，该化合物具有抑制PD-L1表达的效果。该发明的皮里米多皮里米酮化合物可有效用于治疗或预防癌症。
• Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as Raf kinase inhibitors
  申请人：Oslob D. Johan

  公开号：US20060211702A1

  公开（公告）日：2006-09-21

  The present invention provides compounds having the formula: wherein A-B together represent one of the following structures: n, R 1 , R 2 , R 3 , R 4 , L 1 , L 2 , Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of RAF mediated diseases.

  本发明提供了具有以下式子的化合物： 其中 A-B 共同代表下列结构之一： n、R 1 , R 2 , R 3 , R 4 , L 1 , L 2 、Y 和 Z 如本文的类和亚类所定义，及其药物组合物，如本文的一般和亚类所描述，这些化合物可用作蛋白激酶（如 RAF）的抑制剂，因此可用于治疗 RAF 介导的疾病等。